The URGenT Network Services indefinite delivery, indefinite quantity (IDIQ) contract provides neuroscience product developers/innovators with a full range of industry-style, biologic and drug development services and expertise for their development of therapeutics for neurological diseases. These product developers/researchers are funded through other programs at the National Institutes of Health (NIH) but may lack the entire suite of capabilities necessary to advance their candidate product to a phase I clinical trial. Therefore, the IDIQ contract augments the progress of the candidate product by providing the support required at the specific stage of its development and optimization path. The services offered through this contract are bioanalytical assay services and GLP dose-escalation for investigational new drug (IND)-enabling toxicological studies, and support through phase I clinical trial.